BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

...will still take a mezzanine round to clear the path for an IPO. On Thursday, HotSpot Therapeutics Inc....
...kinase C θ S6K1 (RPS6KB1) - Ribosomal protein S6 kinase 70kDa polypeptide 1 Paul Bonanos, Associate Editor HotSpot Therapeutics Inc. Ribosomal...
BioCentury | May 9, 2020
Product Development

With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond

...one other company has taken a DEL company in-house to feed its platform. Last August, HotSpot Therapeutics Inc....
BioCentury | Jan 22, 2020
Emerging Company Profile

Relay’s protein motion platform approaches clinical starting line

...fragments as a starting point for building allosteric modulators, and Black Diamond Therapeutics Inc. and HotSpot Therapeutics Inc....
BioCentury | Sep 13, 2019
Tools & Techniques

Getting higher-quality hits out of DNA-encoded libraries

...Some are bringing the technology in-house to tailor for specific applications, such as allostery company HotSpot Therapeutics Inc....
...Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. GlaxoSmithKline plc (NYSE:GSK, LSE:GSK), London, U.K. HitGen Inc., Chengdu, China HotSpot Therapeutics Inc....
...ENPP2 (ATX) - Autotaxin RIPK1 (RIP1) - Receptor-interacting serine-threonine kinase 1 Allison Johnson, Senior Writer Amgen Inc. GlaxoSmithKline plc HotSpot Therapeutics Inc. Nurix...
BioCentury | Aug 23, 2019
Company News

HotSpot acquires Macroceutics for focused allosteric library

...chemical libraries tailored to allosteric, rather than active, sites. The deal, announced Friday, could help HotSpot Therapeutics Inc....
...and diabetes. Targets: PRKCQ - Protein kinase C θ; S6K - S6 kinase Allison Johnson, Senior Writer HotSpot Therapeutics Inc. Macroceutics...
BioCentury | Jun 20, 2019
Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

...the target and the mechanism of the compound that binds to it aren’t known, said HotSpot Therapeutics Inc....
...Therapeutics S.A. Galactosidase β 1 (GLB1) Endocrine/metabolic Preclinical Glucosylceramidase β (GBA; GCase) Gaucher disease Preclinical HotSpot Therapeutics Inc....
...Src homology protein tyrosine phosphatase 2 Allison Johnson, Staff Writer Black Diamond Therapeutics Inc. Evotec SE GT Gain Therapeutics S.A. HotSpot Therapeutics Inc. Novartis...
BioCentury | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

...pursue other opportunities. He joined the cancer company in 2014 and became CCO in 2016. HotSpot Therapeutics Inc....
BioCentury | Jul 20, 2018
Financial News

Hotspot debuts with $45M to find, drug natural allosteric sites

...Nimbus Therapeutics LLC (Cambridge, Mass.). Atlas' Bruce Booth and Sofinnova's Graziano Seghezzi joined HotSpot's board. HotSpot Therapeutics Inc....
BioCentury | Jul 17, 2018
Financial News

HotSpot debuts with $45M to find, drug natural allosteric sites

HotSpot Therapeutics Inc. (Cambridge, Mass.) emerged from stealth on Tuesday with a $45 million series A round co-led by Atlas Venture and Sofinnova Partners. The company is developing small molecule therapies that imitate natural forms...
BioCentury | Jul 17, 2018
Product R&D

Natural spots

...With a new take on allosteric modulation, HotSpot Therapeutics Inc. has emerged from stealth mode to find specialized...
...bind and regulate the allosteric sites (see “Figure: Finding Your Tail”). Figure: Finding your tail HotSpot Therapeutics Inc....
Items per page:
1 - 10 of 10
BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

...will still take a mezzanine round to clear the path for an IPO. On Thursday, HotSpot Therapeutics Inc....
...kinase C θ S6K1 (RPS6KB1) - Ribosomal protein S6 kinase 70kDa polypeptide 1 Paul Bonanos, Associate Editor HotSpot Therapeutics Inc. Ribosomal...
BioCentury | May 9, 2020
Product Development

With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond

...one other company has taken a DEL company in-house to feed its platform. Last August, HotSpot Therapeutics Inc....
BioCentury | Jan 22, 2020
Emerging Company Profile

Relay’s protein motion platform approaches clinical starting line

...fragments as a starting point for building allosteric modulators, and Black Diamond Therapeutics Inc. and HotSpot Therapeutics Inc....
BioCentury | Sep 13, 2019
Tools & Techniques

Getting higher-quality hits out of DNA-encoded libraries

...Some are bringing the technology in-house to tailor for specific applications, such as allostery company HotSpot Therapeutics Inc....
...Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. GlaxoSmithKline plc (NYSE:GSK, LSE:GSK), London, U.K. HitGen Inc., Chengdu, China HotSpot Therapeutics Inc....
...ENPP2 (ATX) - Autotaxin RIPK1 (RIP1) - Receptor-interacting serine-threonine kinase 1 Allison Johnson, Senior Writer Amgen Inc. GlaxoSmithKline plc HotSpot Therapeutics Inc. Nurix...
BioCentury | Aug 23, 2019
Company News

HotSpot acquires Macroceutics for focused allosteric library

...chemical libraries tailored to allosteric, rather than active, sites. The deal, announced Friday, could help HotSpot Therapeutics Inc....
...and diabetes. Targets: PRKCQ - Protein kinase C θ; S6K - S6 kinase Allison Johnson, Senior Writer HotSpot Therapeutics Inc. Macroceutics...
BioCentury | Jun 20, 2019
Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

...the target and the mechanism of the compound that binds to it aren’t known, said HotSpot Therapeutics Inc....
...Therapeutics S.A. Galactosidase β 1 (GLB1) Endocrine/metabolic Preclinical Glucosylceramidase β (GBA; GCase) Gaucher disease Preclinical HotSpot Therapeutics Inc....
...Src homology protein tyrosine phosphatase 2 Allison Johnson, Staff Writer Black Diamond Therapeutics Inc. Evotec SE GT Gain Therapeutics S.A. HotSpot Therapeutics Inc. Novartis...
BioCentury | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

...pursue other opportunities. He joined the cancer company in 2014 and became CCO in 2016. HotSpot Therapeutics Inc....
BioCentury | Jul 20, 2018
Financial News

Hotspot debuts with $45M to find, drug natural allosteric sites

...Nimbus Therapeutics LLC (Cambridge, Mass.). Atlas' Bruce Booth and Sofinnova's Graziano Seghezzi joined HotSpot's board. HotSpot Therapeutics Inc....
BioCentury | Jul 17, 2018
Financial News

HotSpot debuts with $45M to find, drug natural allosteric sites

HotSpot Therapeutics Inc. (Cambridge, Mass.) emerged from stealth on Tuesday with a $45 million series A round co-led by Atlas Venture and Sofinnova Partners. The company is developing small molecule therapies that imitate natural forms...
BioCentury | Jul 17, 2018
Product R&D

Natural spots

...With a new take on allosteric modulation, HotSpot Therapeutics Inc. has emerged from stealth mode to find specialized...
...bind and regulate the allosteric sites (see “Figure: Finding Your Tail”). Figure: Finding your tail HotSpot Therapeutics Inc....
Items per page:
1 - 10 of 10